Sercombe Lisa, Veerati Tejaswi, Moheimani Fatemeh, Wu Sherry Y, Sood Anil K, Hua Susan
The School of Biomedical Sciences and Pharmacy, The University of Newcastle Callaghan, NSW, Australia ; Hunter Medical Research Institute, New Lambton Heights NSW, Australia.
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA ; Department of Biochemistry and Cell Biology, Rice University Houston, TX, USA.
Front Pharmacol. 2015 Dec 1;6:286. doi: 10.3389/fphar.2015.00286. eCollection 2015.
The application of liposomes to assist drug delivery has already had a major impact on many biomedical areas. They have been shown to be beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution of compounds to target sites in vivo. This enables effective delivery of encapsulated compounds to target sites while minimizing systemic toxicity. Liposomes present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations. Despite considerable research in the last 50 years and the plethora of positive results in preclinical studies, the clinical translation of liposome assisted drug delivery platforms has progressed incrementally. In this review, we will discuss the advances in liposome assisted drug delivery, biological challenges that still remain, and current clinical and experimental use of liposomes for biomedical applications. The translational obstacles of liposomal technology will also be presented.
脂质体在辅助药物递送方面的应用已经对许多生物医学领域产生了重大影响。它们已被证明有利于稳定治疗性化合物、克服细胞和组织摄取的障碍以及改善化合物在体内向靶位点的生物分布。这使得包封的化合物能够有效地递送至靶位点,同时将全身毒性降至最低。脂质体因其灵活的物理化学和生物物理性质而成为一种有吸引力的递送系统,这些性质便于操作以解决不同的递送问题。尽管在过去50年中进行了大量研究且临床前研究取得了大量积极成果,但脂质体辅助药物递送平台的临床转化进展缓慢。在这篇综述中,我们将讨论脂质体辅助药物递送的进展、仍然存在的生物学挑战以及脂质体在生物医学应用中的当前临床和实验用途。还将介绍脂质体技术的转化障碍。